CCM
ATRA icon

Copernicus Capital Management’s Atara Biotherapeutics ATRA Stock Holding History

Copernicus Capital Management’s Portfolio ATRA Stock Details ATRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-2,000
Closed -$778K – 14
2021
Q2 		$778K Buy
+2,000
New +$713K 12.27% 3

Other funds holding ATRA

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Copernicus Capital Management's ATRA Position: Q3 2021 in Review

Copernicus Capital Management sold out of Atara Biotherapeutics (ATRA) in Q3 2021, closing a stake of 2,000 shares — an estimated $778K sold.

Copernicus Capital Management first reported a position in ATRA in Q2 2021 and held it in 1 quarter. The position peaked at $778K in Q2 2021. 140 funds tracked by Wall St. Rank hold ATRA as of Q3 2021.

  • Copernicus Capital Management reported no remaining Atara Biotherapeutics position as of Q3 2021 after selling out during the quarter.
  • Copernicus Capital Management sold 2,000 Atara Biotherapeutics shares in Q3 2021, an estimated $778K.
  • Copernicus Capital Management first reported a position in Atara Biotherapeutics in Q2 2021 and held it in 1 quarter.
  • Copernicus Capital Management's Atara Biotherapeutics position peaked at $778K in Q2 2021.
  • 140 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q3 2021.

Based on Copernicus Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.